SEC Form 4 · accession 0001209191-15-082472
Dare Bioscience, Inc. · DARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David R Walt
Director
Period of report
Nov 25, 2015
Accepted (ET)
Nov 30, 2015 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401914
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 25, 2015 | P | 5,417 | $3.3659 | A | 5,417 | D | |
| Common StockF2 | Nov 27, 2015 | P | 6,700 | $3.2782 | A | 12,117 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $3.35 to $3.41 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.
- F2Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $3.25 to $3.32 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.